ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
ExpreS2ion Biotech Holding AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Helsingborg, SE. The stock last traded at $1.13, up 0.44% on the session, giving a market capitalisation of $2.9M. Its beta of 2.17 implies it has historically moved more than the broad market.
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.
ExpreS2ion Biotech Holding AB (publ) is most often compared with the following Healthcare names: